Home page Home page

Lenvima
lenvatinib

Package leaflet: Information for the user


LENVIMA 4 mg hard capsules LENVIMA 10 mg hard capsules lenvatinib


Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.


Marketing Authorisation Holder

Eisai GmbH

Edmund-Rumpler-Straße 3 60549 Frankfurt am Main Germany

E-mail: medinfo_de@eisai.net

Manufacturer


Eisai GmbH

Edmund-Rumpler-Straße 3 60549 Frankfurt am Main Germany


For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:


België/Belgique/Belgien

Eisai SA/NV

Tél/Tel: + 32 (0) 2 502 58 04

Lietuva

Ewopharma AG atstovybė

Tel: +370 5 2430444


България

Ewopharma AG

Teл.: +359 2 962 12 00

Luxembourg/Luxemburg

Eisai SA/NV

Tél/Tel: + 32 (0) 2 502 58 04

(Belgique/Belgien)


Česká republika

Eisai GesmbH organizačni složka Tel.: + 420 242 485 839

Magyarország Ewopharma Hungary Ltd. Tel.: +36 1 200 46 50


Danmark

Eisai AB

Tlf: + 46 (0) 8 501 01 600

(Sverige)

Malta

Cherubino LTD Tel: +356 21343270

pharmacovigilance@cherubino.com.mt


Deutschland

Eisai GmbH

Tel: + 49 (0) 69 66 58 50

Nederland

Eisai B.V.

Tel: + 31 (0) 900 575 3340


Eesti

Ewopharma AG Eesti filiaal Tel: +372 6015540

Norge

Eisai AB

Tlf: + 46 (0) 8 501 01 600

(Sverige)


Ελλάδα

Arriani Pharmaceutical S.A.

Τηλ: + 30 210 668 3000

Österreich

Eisai GesmbH

Tel: + 43 (0) 1 535 1980-0


España

Eisai Farmacéutica, S.A.

Tel: + (34) 91 455 94 55

Polska

Ewopharma AG Sp. z o.o Tel.: +48 (22) 620 11 71


France

Eisai SAS

Tél: + (33) 1 47 67 00 05

Portugal

Eisai Farmacêutica, Unipessoal Lda

Tel: + 351 214 875 540


Hrvatska Ewopharma d.o.o info@ewopharma.hr

Tel: +385 (0) 1 6646 563

România

Ewopharma AG

Tel: +40 21 260 13 44

Ireland

Eisai GmbH

Tel: + 49 (0) 69 66 58 50

(Germany) Ísland Eisai AB

Sími: + 46 (0) 8 501 01 600

(Svíþjóð)

Slovenija Ewopharma d.o.o. Tel: +386 590 848 40


Slovenská republika

Eisai GesmbH organizační složka Tel.: +420 242 485 839

(Česká republika)


Italia

Eisai S.r.l.

Tel: + 39 02 5181401

Suomi/Finland

Eisai AB

Puh/Tel: + 46 (0) 8 501 01 600

(Ruotsi/Sverige)


Κύπρος

Arriani Pharmaceuticals S.A.

Τηλ: + 30 210 668 3000

(Ελλάδα)

Sverige

Eisai AB

Tel: + 46 (0) 8 501 01 600


Latvija

Ewopharma AG Pārstāvniecība

Tel: +371 67450497

United Kingdom (Northern Ireland)

Eisai GmbH

Tel: + 49 (0) 69 66 58 50

(Germany)


This leaflet was last revised in



Annex IV


Conclusions on the request for one-year marketing protection presented by the European Medicines Agency

Conclusions presented by the European Medicines Agency on:


The CHMP reviewed the data submitted by the marketing authorisation holder, taking into account the provisions of Article 14(11) of Regulation (EC) No 726/2004, and considers that the new therapeutic indication brings significant clinical benefit in comparison with existing therapies as further explained in the European Public Assessment Report.